July 31, 2018 MJ Shareholders
MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQB: MMNFF) announced today the New York Department of Health has approved MedMen’s request to manufacture and sell cannabis-infused lotions and topical pain-alleviating sprays for qualified medical marijuana patients.
MedMen’s four stores in New York currently offer vaporizer pens, tinctures and gel caps in five different formulations. Earlier this year, the state also approved MedMen adding ground flower in the form of metered pods to its product selection.
MedMen is one of only 10 companies licensed to manufacture and sell medical marijuana in New York. In April, MedMen opened its flagship store on Fifth Avenue, only one of three licensed dispensaries in Manhattan.
New York continues to expand its medical marijuana program. Recently, State Health Commissioner Howard Zucker filed emergency regulations allowing cannabis as a substitute for opioids, making medical marijuana legally accessible to patients currently using prescription opioids to treat severe pain.
MedMen operates a cultivation and manufacturing facility in Utica, New York and four dispensaries statewide. The company operates licensed facilities in California and Nevada, and recently signed a definitive agreement to acquire the assets of Florida-based Treadwell Nursery, including rights to open 25 stores in that state.
MedMen Enterprises is a leading cannabis company in the U.S. with assets and operations nationwide. Based in Los Angeles, MedMen brings expertise and capital to the cannabis industry and is one of the nation’s largest financial supporters of progressive marijuana laws. Visit http://www.medmen.com
Source: MedMen Enterprises
Copyright Business Wire 2018
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers